Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells.
Identifieur interne : 000339 ( Main/Exploration ); précédent : 000338; suivant : 000340Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells.
Auteurs : RBID : pubmed:23382117English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Cancer Vaccines (immunology), Cancer Vaccines (therapeutic use), Cell Movement, Dendritic Cells (cytology), Dendritic Cells (immunology), Dendritic Cells (transplantation), Female, Granulocyte-Macrophage Colony-Stimulating Factor (metabolism), Humans, Lymph Nodes (cytology), Lymph Nodes (immunology), Lymph Nodes (pathology), Male, Melanoma (immunology), Melanoma (pathology), Melanoma (therapy), Middle Aged, Neoplasm Staging, Organometallic Compounds (chemistry), Oxyquinoline (analogs & derivatives), Oxyquinoline (chemistry), T-Lymphocytes, Cytotoxic (immunology).
- MESH :
- chemical , analogs & derivatives : Oxyquinoline.
- chemical , chemistry : Organometallic Compounds, Oxyquinoline.
- chemical , immunology : Cancer Vaccines.
- chemical , metabolism : Granulocyte-Macrophage Colony-Stimulating Factor.
- chemical , therapeutic use : Cancer Vaccines.
- cytology : Dendritic Cells, Lymph Nodes.
- immunology : Dendritic Cells, Lymph Nodes, Melanoma, T-Lymphocytes, Cytotoxic.
- pathology : Lymph Nodes, Melanoma.
- therapy : Melanoma.
- transplantation : Dendritic Cells.
- Adolescent, Adult, Aged, Cell Movement, Female, Humans, Male, Middle Aged, Neoplasm Staging.
Abstract
Anticancer dendritic cell (DC) vaccines require the DCs to relocate to lymph nodes (LN) to trigger immune responses. However, these migration rates are typically very poor. Improving the targeting of ex vivo generated DCs to LNs might increase vaccine efficacy and reduce costs. We investigated DC migration in vivo in humans under different conditions.
DOI: 10.1158/1078-0432.CCR-12-1879
PubMed: 23382117
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells.</title><author><name sortKey="Aarntzen, Erik H J G" uniqKey="Aarntzen E">Erik H J G Aarntzen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen</wicri:regionArea></affiliation></author><author><name sortKey="Srinivas, Mangala" uniqKey="Srinivas M">Mangala Srinivas</name></author><author><name sortKey="Bonetto, Fernando" uniqKey="Bonetto F">Fernando Bonetto</name></author><author><name sortKey="Cruz, Luis J" uniqKey="Cruz L">Luis J Cruz</name></author><author><name sortKey="Verdijk, Pauline" uniqKey="Verdijk P">Pauline Verdijk</name></author><author><name sortKey="Schreibelt, Gerty" uniqKey="Schreibelt G">Gerty Schreibelt</name></author><author><name sortKey="Van De Rakt, Mandy" uniqKey="Van De Rakt M">Mandy van de Rakt</name></author><author><name sortKey="Lesterhuis, W Joost" uniqKey="Lesterhuis W">W Joost Lesterhuis</name></author><author><name sortKey="Van Riel, Maichel" uniqKey="Van Riel M">Maichel van Riel</name></author><author><name sortKey="Punt, Cornelius J A" uniqKey="Punt C">Cornelius J A Punt</name></author><author><name sortKey="Adema, Gosse J" uniqKey="Adema G">Gosse J Adema</name></author><author><name sortKey="Heerschap, Arend" uniqKey="Heerschap A">Arend Heerschap</name></author><author><name sortKey="Figdor, Carl G" uniqKey="Figdor C">Carl G Figdor</name></author><author><name sortKey="Oyen, Wim J" uniqKey="Oyen W">Wim J Oyen</name></author><author><name sortKey="De Vries, I Jolanda M" uniqKey="De Vries I">I Jolanda M de Vries</name></author></titleStmt><publicationStmt><date when="2013">2013</date><idno type="doi">10.1158/1078-0432.CCR-12-1879</idno><idno type="RBID">pubmed:23382117</idno><idno type="pmid">23382117</idno><idno type="wicri:Area/Main/Corpus">000818</idno><idno type="wicri:Area/Main/Curation">000818</idno><idno type="wicri:Area/Main/Exploration">000339</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Cancer Vaccines (immunology)</term><term>Cancer Vaccines (therapeutic use)</term><term>Cell Movement</term><term>Dendritic Cells (cytology)</term><term>Dendritic Cells (immunology)</term><term>Dendritic Cells (transplantation)</term><term>Female</term><term>Granulocyte-Macrophage Colony-Stimulating Factor (metabolism)</term><term>Humans</term><term>Lymph Nodes (cytology)</term><term>Lymph Nodes (immunology)</term><term>Lymph Nodes (pathology)</term><term>Male</term><term>Melanoma (immunology)</term><term>Melanoma (pathology)</term><term>Melanoma (therapy)</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Organometallic Compounds (chemistry)</term><term>Oxyquinoline (analogs & derivatives)</term><term>Oxyquinoline (chemistry)</term><term>T-Lymphocytes, Cytotoxic (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Oxyquinoline</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Organometallic Compounds</term><term>Oxyquinoline</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Cancer Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Granulocyte-Macrophage Colony-Stimulating Factor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cancer Vaccines</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Dendritic Cells</term><term>Lymph Nodes</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Dendritic Cells</term><term>Lymph Nodes</term><term>Melanoma</term><term>T-Lymphocytes, Cytotoxic</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lymph Nodes</term><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Dendritic Cells</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Cell Movement</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Anticancer dendritic cell (DC) vaccines require the DCs to relocate to lymph nodes (LN) to trigger immune responses. However, these migration rates are typically very poor. Improving the targeting of ex vivo generated DCs to LNs might increase vaccine efficacy and reduce costs. We investigated DC migration in vivo in humans under different conditions.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23382117</PMID><DateCreated><Year>2013</Year><Month>03</Month><Day>18</Day></DateCreated><DateCompleted><Year>2013</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-0432</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>6</Issue><PubDate><Year>2013</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title><ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation></Journal><ArticleTitle>Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells.</ArticleTitle><Pagination><MedlinePgn>1525-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-12-1879</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Anticancer dendritic cell (DC) vaccines require the DCs to relocate to lymph nodes (LN) to trigger immune responses. However, these migration rates are typically very poor. Improving the targeting of ex vivo generated DCs to LNs might increase vaccine efficacy and reduce costs. We investigated DC migration in vivo in humans under different conditions.</AbstractText><AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">HLA-A*02:01 patients with melanoma were vaccinated with mature DCs loaded with tyrosinase and gp100 peptides together with keyhole limpet hemocyanin (NCT00243594). For this study, patients received an additional intradermal vaccination with (111)In-labeled mature DCs. The injection site was pretreated with nonloaded, activated DCs, TNFα, or Imiquimod; granulocyte macrophage colony-stimulating factor was coinjected or smaller numbers of DCs were injected. Migration was measured by scintigraphy and compared with an intrapatient control vaccination. In an ex vivo tissue model, we measured CCL21-directed migration of (19)F-labeled DCs over a period of up to 12 hours using (19)F MRI to supplement our patient data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Pretreatment of the injection site induced local inflammatory reactions but did not improve migration rates. Both in vitro and in vivo, reduction of cell numbers to 5 × 10(6) or less cells per injection improved migration. Furthermore, scintigraphy is insufficient to study migration of such small numbers of (111)In-labeled DCs in vivo.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Reduction of cell density, not pretreatment of the injection site, is crucial for improved migration of DCs to LNs in vivo.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aarntzen</LastName><ForeName>Erik H J G</ForeName><Initials>EH</Initials><Affiliation>Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen, The Netherlands.</Affiliation></Author><Author ValidYN="Y"><LastName>Srinivas</LastName><ForeName>Mangala</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bonetto</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Luis J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Verdijk</LastName><ForeName>Pauline</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Schreibelt</LastName><ForeName>Gerty</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>van de Rakt</LastName><ForeName>Mandy</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lesterhuis</LastName><ForeName>W Joost</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>van Riel</LastName><ForeName>Maichel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Punt</LastName><ForeName>Cornelius J A</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Adema</LastName><ForeName>Gosse J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Heerschap</LastName><ForeName>Arend</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Figdor</LastName><ForeName>Carl G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Oyen</LastName><ForeName>Wim J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>de Vries</LastName><ForeName>I Jolanda M</ForeName><Initials>IJ</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00243594</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>NS045062</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType>Clinical Trial</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, N.I.H., Extramural</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Cancer Res</MedlineTA><NlmUniqueID>9502500</NlmUniqueID><ISSNLinking>1078-0432</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Cancer Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Organometallic Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>14514-42-2</RegistryNumber><NameOfSubstance>indium oxine</NameOfSubstance></Chemical><Chemical><RegistryNumber>5UTX5635HP</RegistryNumber><NameOfSubstance>Oxyquinoline</NameOfSubstance></Chemical><Chemical><RegistryNumber>83869-56-1</RegistryNumber><NameOfSubstance>Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cancer Vaccines</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cell Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Dendritic Cells</DescriptorName><QualifierName MajorTopicYN="N">cytology</QualifierName><QualifierName MajorTopicYN="Y">immunology</QualifierName><QualifierName MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName MajorTopicYN="N">cytology</QualifierName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Melanoma</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Organometallic Compounds</DescriptorName><QualifierName MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Oxyquinoline</DescriptorName><QualifierName MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2013</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2013</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">1078-0432.CCR-12-1879</ArticleId><ArticleId IdType="doi">10.1158/1078-0432.CCR-12-1879</ArticleId><ArticleId IdType="pubmed">23382117</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000339 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000339 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23382117
|texte= Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23382117" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |